Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
10275 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 141,438 | 323,169 | 234,314 | 124,451 | |||
| Cash and cash equivalent | 28,038 | 43,069 | 59,714 | 54,951 | |||
| Short-term investments | 113,400 | 280,100 | 174,600 | 69,500 | |||
| Restricted cash and investments | 243 | ||||||
| Receivables | 5,874 | 2,377 | 417 | ||||
| Prepaid expense | 747 | 1,018 | 990 | 1,021 | |||
| Other undisclosed current assets | 354,533 | 121,872 | 112,846 | 219,215 | |||
| Total current assets: | 496,718 | 451,933 | 350,770 | 345,104 | |||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 35,916 | 42,373 | 44,691 | 2,520 | |||
| Property, plant and equipment | 5,819 | 7,705 | 8,148 | 1,099 | |||
| Long-term investments and receivables | 21,213 | 37,495 | |||||
| Long-term investments | 21,213 | 37,495 | |||||
| Intangible assets, net (including goodwill) | 3,736 | 3,736 | 3,736 | 12,536 | |||
| Goodwill | 3,736 | 3,736 | 3,736 | 3,736 | |||
| Intangible assets, net (excluding goodwill) | 8,800 | ||||||
| Restricted cash and investments | 2,681 | 2,627 | 2,627 | 1,320 | |||
| Deferred income tax assets | |||||||
| Other undisclosed noncurrent assets | 6,818 | 9,723 | 7,040 | 2,976 | |||
| Total noncurrent assets: | 54,970 | 87,377 | 103,737 | 20,451 | |||
| TOTAL ASSETS: | 551,688 | 539,310 | 454,507 | 365,555 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 69,367 | 56,647 | 43,944 | 28,601 | |||
| Accounts payable | 14,926 | 11,247 | 11,590 | 8,661 | |||
| Accrued liabilities | 54,441 | 45,400 | 32,354 | 19,940 | |||
| Total current liabilities: | 69,367 | 56,647 | 43,944 | 28,601 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation: | 44,459 | ||||||
| Liabilities, other than long-term debt | 44,930 | 48,639 | 1,622 | 3,577 | |||
| Deferred income tax liabilities | 853 | 1,622 | 2,480 | ||||
| Other liabilities | 1,780 | 2,620 | 1,097 | ||||
| Operating lease, liability | 43,150 | 45,166 | 44,459 | ||||
| Total noncurrent liabilities: | 44,930 | 48,639 | 46,081 | 3,577 | |||
| Total liabilities: | 114,297 | 105,286 | 90,025 | 32,178 | |||
| Equity | |||||||
| Equity, attributable to parent | 437,284 | 433,803 | 363,954 | 308,582 | |||
| Common stock | 70 | 59 | 45 | 41 | |||
| Additional paid in capital | 1,323,576 | 1,031,462 | 723,593 | 509,339 | |||
| Accumulated other comprehensive income (loss) | 2,194 | (1,353) | (125) | 36 | |||
| Accumulated deficit | (888,556) | (596,365) | (359,559) | (200,834) | |||
| Equity, attributable to noncontrolling interest | 107 | ||||||
| Other undisclosed equity | 221 | 528 | 24,795 | ||||
| Total equity: | 437,391 | 434,024 | 364,482 | 333,377 | |||
| TOTAL LIABILITIES AND EQUITY: | 551,688 | 539,310 | 454,507 | 365,555 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Revenues | 900 | |||||
| Sublease income | 900 | |||||
| Gross profit: | 900 | |||||
| Operating expenses | (299,509) | (227,287) | (216,542) | (118,787) | ||
| Other undisclosed operating loss | (900) | |||||
| Operating loss: | (299,509) | (227,287) | (216,542) | (118,787) | ||
| Nonoperating income (expense) (Investment Income, Nonoperating) | 50,674 | (556) | ||||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 22,617 | 5,987 | (522) | 1,239 | ||
| Loss from continuing operations before equity method investments, income taxes: | (276,892) | (221,300) | (166,390) | (118,104) | ||
| Loss from equity method investments | (16,014) | (16,282) | (1,831) | |||
| Other undisclosed income from continuing operations before income taxes | 3,662 | |||||
| Loss from continuing operations before income taxes: | (292,906) | (237,582) | (164,559) | (118,104) | ||
| Income tax expense (benefit) | 601 | 469 | 297 | (444) | ||
| Loss from continuing operations: | (292,305) | (237,113) | (164,262) | (118,548) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (164,262) | (118,548) | |
| Other undisclosed net loss | (1,831) | |||||
| Net loss: | (292,305) | (237,113) | (166,093) | (118,548) | ||
| Net income attributable to noncontrolling interest | 114 | 307 | 7,368 | 707 | ||
| Net loss available to common stockholders, diluted: | (292,191) | (236,806) | (158,725) | (117,841) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Net loss: | (292,305) | (237,113) | (166,093) | (118,548) | ||
| Other undisclosed comprehensive income (loss) | 3,547 | (1,228) | (161) | 36 | ||
| Comprehensive loss: | (288,758) | (238,341) | (166,254) | (118,512) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 114 | 307 | 7,368 | 707 | ||
| Comprehensive loss, net of tax, attributable to parent: | (288,644) | (238,034) | (158,886) | (117,805) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.